A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

NCT05829226 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

AML, Adult Recurrent
MDS

Interventions

DRUG: LYT-200
DRUG: Venetoclax
DRUG: Azacitidine
DRUG: Decitabine

Sponsor

PureTech